| Symbol | AVTX |
|---|---|
| Name | AVALO THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 540 GAITHER ROAD,SUITE 400, ROCKVILLE, Maryland, 20850, United States |
| Telephone | +1 410 522-8707 |
| Fax | — |
| — | |
| Website | https://www.avalotx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006. Additional info from NASDAQ: |
New Form DEFA14A - Avalo Therapeutics, Inc. <b>Filed:</b> 2026-04-10 <b>AccNo:</b> 0001534120-26-000023 <b>Size:</b> 375 KB
Read moreDoyle Mittie 🟡 adjusted position in 4.0K shares (1 derivative) of Avalo Therapeutics, Inc. (AVTX) at $18.01 Transaction Date: Apr 06, 2026 | Filing ID: 000008
Read more📋 MITTIE DOYLE (Officer) plans to sell 66K shares of AVALO THERAPEUTICS INC (at $17.76 each, total $1.2M) Filed: Apr 06, 2026 | ID: 003276
Read moreSullivan Christopher Ryan 🔴 sold 16.0K shares of Avalo Therapeutics, Inc. (AVTX) at $17.57 Transaction Date: Apr 01, 2026 | Filing ID: 000006
Read moreDoyle Mittie 🟡 adjusted position in 679 shares (1 derivative) of Avalo Therapeutics, Inc. (AVTX) at $16.00 Transaction Date: Apr 01, 2026 | Filing ID: 000006
Read more📋 CHRISTOPHER SULLIVAN (Officer) plans to sell 16K shares of AVALO THERAPEUTICS INC (at $14.93 each, total $238K) Filed: Apr 01, 2026 | ID: 003175
Read moreJain Rita 🟢 acquired 1.3K shares (1 derivative) of Avalo Therapeutics, Inc. (AVTX) at $14.93 Transaction Date: Mar 31, 2026 | Filing ID: 000003
Read moreLind Kevin Robert 🟢 acquired 1.4K shares (1 derivative) of Avalo Therapeutics, Inc. (AVTX) at $14.93 Transaction Date: Mar 31, 2026 | Filing ID: 000002
Read moreNew Form SCHEDULE 13G - Avalo Therapeutics, Inc. <b>Filed:</b> 2026-04-01 <b>AccNo:</b> 0000935836-26-000188 <b>Size:</b> 21 KB
Read more(99% Neutral) AVALO THERAPEUTICS, INC. (AVTX) Announces Director Election
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05288504 | A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Po… | Phase2 | Non-Eosinophilic Asthma | Completed | 2022-02-24 | 2023-05-11 | ClinicalTrials.gov |
| NCT01579526 | A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozeng… | Phase1 | Healthy | Completed | 2012-04-01 | 2012-05-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 2 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 1 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 2 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 1 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 2 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 1 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 2 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 1 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 2 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 1 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 2 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 1 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 2 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 1 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 2 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 1 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 2 | DRUG | Phase PHASE2 | Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | NCT06603077 |
| AVTX-009 Regimen 1 | DRUG | Phase PHASE2 | Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | NCT06603077 |
| AVTX-002 | DRUG | Phase PHASE2 | Non-Eosinophilic Asthma | COMPLETED | NCT05288504 |
| CERC-006 | DRUG | Phase PHASE1 | Lymphatic Malformation | WITHDRAWN | NCT04994002 |
| AEVI-007 | DRUG | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT04671251 |
| MDGN-002 | DRUG | Phase PHASE1 | Crohn Disease | TERMINATED | NCT03169894 |
| Placebo | DRUG | Phase PHASE2 | Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | NCT06603077 |
| CERC-301 | DRUG | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT02459236 |
| placebo | DRUG | Phase PHASE2 | Chronic Refractory Cough | COMPLETED | NCT01703923 |
| FP01 | DRUG | Phase PHASE2 | Chronic Refractory Cough | COMPLETED | NCT01703923 |